326827-21-8

Basic information

• Product Name: 3-Amino-5-cyclobutyl-1H-pyrazole
• Synonyms: 3-Amino-5-cyclobutyl-1H-pyrazole;3-AMino-5-cyclobutyl-1H-p...;5-Cyclobutyl-1H-pyrazol-3-aMine;3-AMino-5-cyclobutyl-2H-pyrazole;1H-Pyrazol-3-amine, 5-cyclobutyl-
• CAS NO: 326827-21-8
• Molecular Formula: C₇H₁₁N₃
• Molecular Weight: 137.18
• Mol File: 326827-21-8.mol

Chemical Properties

• Boiling Point: 368.058 °C at 760 mmHg
• Flash Point: 204.049 °C
• Appearance: /
• Density: 1.258 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 15.68±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3-Amino-5-cyclobutyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-5-cyclobutyl-1H-pyrazole(326827-21-8)
• EPA Substance Registry System: 3-Amino-5-cyclobutyl-1H-pyrazole(326827-21-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 326827-21-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Amino-5-cyclobutyl-1H-pyrazole serves as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of diverse chemical entities through reactions such as substitution, addition, and condensation.
Used in Pharmaceuticals:
In the pharmaceutical industry, 3-Amino-5-cyclobutyl-1H-pyrazole is utilized as a building block for the development of new drugs. Its presence in a molecule can impart specific biological activities, making it a valuable component in the design of therapeutic agents.
Used in Agrochemicals:
3-Amino-5-cyclobutyl-1H-pyrazole is employed as a raw material in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields.
Used in Dyestuff:
In the dyestuff industry, 3-Amino-5-cyclobutyl-1H-pyrazole is used as an intermediate for the synthesis of various dyes and pigments. Its ability to form colored compounds makes it a useful component in the creation of a wide range of colorants for different applications.

InChI:InChI=1/C7H11N3/c8-7-4-6(9-10-7)5-2-1-3-5/h4-5H,1-3H2,(H3,8,9,10)

Upstream product

• 118431-89-3 β-Cyclobutyl-β-oxopropionitrile 

Downstream Products

• 1315585-50-2 (S)-N-(4-(4-(5-cyclobuty1-1H-pyrazol-3-ylamino)pyrrolo[2,1-f][1,2,4]triazin-2-ylthio)phenyl)-2-(4.4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl)acetamide 
• 1315590-94-3 2-chloro-N-(4-(4-(5-cyclobutyl-1H-pyrazol-3-ylamino)pyrrolo[2,1-f][1,2,4]triazin-2-ylthio)phenyl)acetamide 
• 1315590-93-2 2-(4-aminophenylthio)-N-(5-cyclobutyl-1H-pyrazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine 
• 1204243-98-0 (4-(5-cyclobutyl-1H-pyrazol-3-ylamino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)(4-fluorophenyl)methanone 
• 817640-91-8 4-(4-Chloro-phenyl)-3-cyclobutyl-2,4,5,7-tetrahydro-pyrazolo[3,4-b]pyridin-6-one 

Relevant articles and documents

INHIBITORS OF TYROSINE KINASE

The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kin

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treat

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors

The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2 and R3 are as defined herein; pharmaceutical formulations thereof; and use thereof in the treatment of, inter alia, conditions, diseases, and symptoms such as bipolar disorder, diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.